Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037869
Status:
COMPLETED
Last Update Posted:
2018-10-31
First Post:
2002-05-24
Brief Title:
High Dose I-131 MetaiodobenzylguanidineMIBG for Metastatic Neuroendocrine Tumors
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
High Dose I-131 Metaiodobenzylguanidine MIBG Therapy for Metastatic Neuroendocrine Tumors
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine MIBG can shrink or slow the growth of the tumors in patients with metastatic neuroendocrine tumors The safety of this treatment will also be studied
Detailed Description:
MIBG is used to visualize a group of specific cells in the body It has been known to deliver the radioactive iodine to the tumor cancer cells selectively and result in their destruction
Before treatment starts patients will be evaluated with a tracer scan using either I-131 MIBG or I-123 MIBG to locate the tumor sites If no MIBG accumulation can be found within tumor sites the patient will not be able to continue on this study Patients will also have CT scans and urine and blood tests Women able to have children will have a pregnancy test
If tumor sites are found and patients are fully eligible they will receive a therapeutic treatment dose of I-131 MIBG by vein over 120 minutes Some patients may have to receive a lower dose of MIBG Patients will require hospitalization for treatment and will remain hospitalized for about 3-6 days
Before treatment starts patients will be evaluated with a tracer scan using either I-131 MIBG or I-123 MIBG to locate the tumor sites If no MIBG accumulation can be found within tumor sites the patient will not be able to continue on this study Patients will also have CT scans and urine and blood tests Women able to have children will have a pregnancy test
If tumor sites are found and patients are fully eligible they will receive a therapeutic treatment dose of I-131 MIBG by vein over 120 minutes Some patients may have to receive a lower dose of MIBG Patients will require hospitalization for treatment and will remain hospitalized for about 3-6 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None